Triamcinolone acetonide sustained-release - Flexion Therapeutics

Drug Profile

Triamcinolone acetonide sustained-release - Flexion Therapeutics

Alternative Names: FX-006; Zilretta

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Flexion Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glucocorticoid receptor agonists; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Musculoskeletal pain

Most Recent Events

  • 08 Aug 2017 Flexion Therapeutics completes enrolment in the phase III trial for Musculoskeletal pain (associated with knee osteoarthritis) in USA (Intra-articular)
  • 08 Aug 2017 Flexion Therapeutics plans clinical trials for Musculoskeletal pain (associated with osteoarthritis of the hip and shoulder) by the end of 2017
  • 10 Jul 2017 Flexion Therapeutics plans to launch of triamcinolone acetonide in Q4 2017, pending regulatory approval from the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top